Last reviewed · How we verify

Trauma

NWTraumatherapies · FDA-approved active Small molecule ✓ Verified May 2026

Trauma is a Small molecule drug developed by NWTraumatherapies. It is currently FDA-approved. Also known as: psilocybin.

Trauma can refer to severe mental and emotional injury caused by distressing events, or sudden physical injury caused by an external force. Desmopressin acetate, a vasopressin receptor agonist, has been studied in clinical trials for various conditions including Traumatic Brain Injury, Dental Extraction, Wound Heal, Pressure Injuries, and Spinal Cord Injuries.

At a glance

Generic nameTrauma
Also known aspsilocybin
SponsorNWTraumatherapies
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Trauma

What is Trauma?

Trauma is a Small molecule drug developed by NWTraumatherapies.

Who makes Trauma?

Trauma is developed and marketed by NWTraumatherapies (see full NWTraumatherapies pipeline at /company/nwtraumatherapies).

Is Trauma also known as anything else?

Trauma is also known as psilocybin.

What development phase is Trauma in?

Trauma is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing